γδ T cells are one of the important T cell groups in innate immunity in the body, with antigen-specific recognition function without MHC restriction. plays an important role in cancer and other processes. This platform refers to in vitro stimulation of γδ T cells in human peripheral blood.

 

The technology can effectively expand the γδ T cells in the peripheral blood of tumor patients in vitro, and use its own APC function to prepare targeted γδ T cells. The most important technical core of this technology is the establishment of a γδ T cell culture system. We have completely independent intellectual property rights for this culture body, and a related invention patent has been accepted for a method for preparing targeted γδ T cells with polypeptides (accepted patent No. 20171007079 0.4) and a preparation method of tumor-specific γδ T cells (authorized patent number ZL201711364820.9). At present, this technology platform can effectively amplify γδ T cells in peripheral blood of patients with various early and advanced tumors such as breast cancer, prostate cancer, kidney cancer, bladder cancer, and lung cancer.